Skip to Content

New Drug Approvals Archive - October 2005

See also: New Indications and Dosage Forms for October 2005

October 2005

Flexbumin (albumin human) Solution

Date of Approval: October 17, 2005
Company: Baxter Healthcare Corporation
Treatment for: Plasma Volume Expansion

Flexbumin (albumin human) is the first human serum albumin preparation packaged in a flexible container (previously packaged in glass bottles). Flexbumin is indicated in hypovolemia, hypoalbuminemia due to inadequate reproduction, excessive catabolism, hemorrhage, major surgery or burns, and for use during cardiopulmonary bypass surgery.

Arranon (nelarabine) Injection

Date of Approval: October 28, 2005
Company: GlaxoSmithKline
Treatment for: Acute Lymphoblastic Leukemia, Lymphoma

Arranon (nelarabine) is a chemotherapy agent indicated for the treatment of adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Soltamox (tamoxifen) Oral Solution

Date of Approval: October 29, 2005
Company: Savient Pharmaceuticals, Inc.
Treatment for: Breast Cancer

Soltamox is an oral liquid formulation of tamoxifen indicated for the treatment of breast cancer.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.